Johnson & Johnson   3Q Revenues: $15 billion (+13%) 3Q Earnings: $2.5 billion (-8%) YTD Revenues: $45.1 billion (+14%) YTD Earnings: $8.2 billion (-8%) Comments: Worldwide pharmaceutical sales were $6.1 billion in the quarter, up 4%. Growth reflects the strong performance of Topamax, Remicade, and antipsychotic franchise, which includes Risperdal, Risperdal Consta and Invega. Earnings for the quarter include an after-tax restructuring charge of $528 million associated with a c...